Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
Biogen, Ionis' partner, announced topline results from the Phase 2 CELIA study of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau in early Alzheimer’s disease. The study demonstrated robust reductions in tau pathology across all doses and cognitive benefit, particularly at the lowest dose of 60 mg every 24 weeks. Despite not meeting the primary endpoint, Biogen plans to advance diranersen to registrational development, indicating strong confidence in the drug's potential.
Key figures
- Drug Name
- diranersen (BIIB080)
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.